Condition
Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 74/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results67% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 2 (1)
Trial Status
Completed2
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT03458364Not ApplicableCompletedPrimary
Comparison of HFNC With NIV in Weaning COPD
NCT01473758Phase 2TerminatedPrimary
Effect of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease
NCT02321215Not ApplicableCompletedPrimary
Effectiveness and Feasibility of Delivering an Education Program to Patients With an Acute Exacerbation of COPD
Showing all 3 trials